Tag: FDA warning
An Analysis of the Intended Use of Atypical Antipsychotics in Dementia
by Jeff Ventimiglia, BSE; Amir H. Kalali, MD; Ipsit V. Vahia, MD; and Dilip V. Jeste, MD Mr. Ventimiglia is an analyst in Clinical Strategy and Solutions, Quintiles, Inc., in Durham, North Carolina; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego in […]
